GRAIL Heads Into Print With Options at a Year-High Hedge and 20% Short Float

GRAL reports after the close on August 12 carrying one of the most heavily hedged options setups it has seen all year — a notable signal for a stock already under significant short-seller pressure.

The clearest pre-earnings tell is in options. The put/call ratio jumped to 0.81 on Monday, more than three standard deviations above its 20-day average of 0.69 — and that reading is the highest of the past 52 weeks. That kind of defensive positioning, appearing right at the edge of the stock's recent history, suggests options traders are paying up for downside protection at an unusual clip ahead of the print. The stock has added 7.7% in a single session and 6.5% over the past week, closing at $74.84, so the hedging is running alongside — not against — a sharp near-term rally.

Short interest adds a separate layer of complexity. Nearly 20% of GRAL's free float is currently sold short, a level that has been broadly stable over the past month but ticked up roughly 8% over that period. Days to cover sits at 15.5, meaning any sharp move against the bears takes meaningful time to unwind. Yet the borrow market is not under stress: availability has actually loosened sharply, rising 57% over the past week to roughly 296% — meaning there are nearly three shares available for every one currently borrowed. Cost to borrow is negligible at 0.50%. That combination — heavy short positioning, ample borrow supply — points to a crowded but not cornered short base. The ORTEX short score of 72.8 ranks in the bottom decile of the universe for short-side risk, reinforcing that reading.

The bull-bear divide heading into the print is rooted in GRAIL's clinical and regulatory story rather than its financials. Bulls point to a $100 billion multi-cancer early detection market, 27% projected revenue growth, and a competitive moat in the liquid biopsy space that few rivals can replicate. Bears are focused on two specific setbacks: the NHS-Galleri trial missed its primary endpoint, and the FDA review remains in an iterative stage — both of which cloud the commercialisation timeline for the Galleri test. Analysts broadly hold Neutral ratings, with Goldman Sachs initiating at Neutral and a $60 target in June, and Mizuho lifting its Neutral target to $65 in mid-July. TD Cowen sits at Buy with a $69 target. The consensus mean of $70 now sits below the current price of $74.84, which means the stock has effectively rallied through the Street's collective ceiling ahead of results. The sole recent Buy from Guggenheim carries a $75 target, suggesting even the most constructive published view is barely above where the stock closed Monday.

On the institutional side, Baker Bros. Advisors holds 9% of shares and added nearly 2 million shares in Q1. Farallon and Sessa Capital both built significant positions in the same period. That concentration among specialist healthcare and hedge fund investors means the shareholder base is likely sensitive to any clinical or commercial signal in the release. Illumina, the former parent, trimmed its stake by 1.2 million shares as recently as February — a notable departure by an insider with deep knowledge of the asset.

The August 12 print will test whether GRAIL's revenue trajectory and any regulatory updates can justify a stock trading above every analyst's published target, with two-thirds of options players now positioned for a down move.